Please type a plus sign (+) inside this box Under the Paperwork Reduction Act of 1995; no persons are required to r				PTO/SB/08A (08-00) Approved for use through 10/31/2002, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE respond to a collection of information unless it contains a valid OMB control number.				
		ila for form 1449A				omplete if Known	A THE STATE OF	HUCF.
	10.15			21 221122	Application Number	09/891,023		
	INFORMATION DISCLOSURE				Filing Date	06-25-01	-E	
TPEV	STA	STATEMENT BY APPLICANT			First Named Inventor	Janigro		
. , V					Group Art Unit	1645 1647	<u> </u>	_
<u> </u>	λ	(use as many s	sneers as n	ecessary)	Examiner Name	Unknown Nichols	2	Ź
0 7 2002	Sheet	l	of	2	Attorney Dockel Number	26336-8	<u>L.</u> ;	
	7				·			

Examil	U.S. PATENT DOCUMENTS					
Initials	No.		Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Ling S Where Relevant Passages or Relevant Figures Appear
100	AA	6,268,223	B1	Comell-Bell et al.	07/31/2001	LIMITER APPEAL
(3)	O AB	6,117,989		Bandman et al.	09/12/2000 -	
9		5,866,347		Swedo et al.	02/02/1999	
८०	AD	5,304,367		Biegon	04/19/1994 -	
	AE					
_	AF					
	AG					
	AH					
	AI					
	AJ	 				
<u> </u>	AK	 				
ļ	AL	<u> </u>				
	AM					
. ()	AN					
	AO	-				
	AP					
-	AQ	 	_			
-	AR	 		· · · · · · · · · · · · · · · · · · ·		
<u></u>	AS	ļ		· · · · · · · · · · · · · · · · · · ·		
	AT	<u> </u>				

			· · · ·	FORE	IGN PATENT DOCUMEN	TS .		
Examiner Initials	No.1	Foreign Patent Document			No.	Date of Publication of	Pages, Columns, Lines.	T
		Office ³	Number ⁴	Kind Code ^s (if known)	Name of Patentes or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	1
	AT			7				+
	۸V		·-					+-
	۸W							+
	ΑX						<u> </u>	+-
								╁
								†
								†-
	1						<u> </u>	t^-
								†-
								┿

Examiner		Date	
01			1122127
Signature	rolla las	Considered	114(11(1)5)

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of his form with next communication to applicant.

^{*} Unique citation designation number. 3 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the palent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box — + Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449B/PTO **Application Number** 09/891,023 **INFORMATION DISCLOSURE Filing Date** 06-25-01 STATEMENT BY APPLICANT First Named Inventor **Janigro** Group Art Unit 1643 (64) (use as many sheets as necessary) Examiner Name Unknown Sheet Attorney Docket Number 26336-8 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the

۶	Examiner Initials	Cite No.¹	publisher, city and/or country where published.	T2
	CS	BA	Tumor Markers in Peripheral Blood of Patients with Malignant Melanoma: Multimarker RT-PCR Versus a Luminoimmunometric Assay for S-100; Berking, Carola et al.; Arch Dermatol Res (1999) 291: 479-484.	7
	005	ВВ	Evaluation of Serum Markers of Neuronal Damage Following Severe Hypoglycaemia in Adults with Insulin-Treated Diabetes Mellitus; Strachan, Mark, W., et al.; Diabetes/Metabolism Research & Reviews 1999; 15: 5-12.	-
	45	ВС	Outwitting the Blood-Brain Barrier for Therapeutic Purposes: Osmotic Opening and Other Means; Kroll, Robert A. & Neuwelt, Edward A.; Neurosurgery, Vol. 42, No. 5; May 1998.	
	9	BD	Autoantibodies in Neuerdegenerative Diseases: Antigen-Specific Frequencies and Intrathecal Analysis; Terryberry, J.W. et al.; Neurobiology of Aging, Vol. 19, No. 3, pp. 205-216, 1998.	
	COS	BE	Cerebrospinal Fluid Analysis Differentiates Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis; Jongen, Peter J. H. et al., Neurol Neurosurg Psychiatry 1997; 63:446-451.	_
	CZ	BF	S-100 Release in Hypothermic Circulatory Arrest and Coronary Artery Surgery; Wong, Carl II. et al.; Ann Thorac Surg 1999; 67:1911-4.	
	03	BG	Serum S100 Protein: A Potential Marker for Cerebral Events During Cardiopulmonary Bypass; Westbay, Stephen et al.; Ann Thorac Surg 1996; 61:88-92.	
	CZ	BII	Scrum anti-GFAP ad anti-S100 autoantibodies in brain aging, Alzheimer's disease and vascular dementia; Mecocci, P. et al.; Journal of Neuroimmunology 57 (1995) 165-170.	
1	(D)	Ві	Uncontrolled Reoxygenation by Initiating Cardiopulinonary bypass is Associated with Higher Protein \$100 in Cyanotic Versus Acyanotic Patients; Matheis, G. et al.; Thorac Cardiov Surg 2000; 48: 263-268.	
		Bì		
		ВК		

		• -
Evaminac I		
Examiner	Date	,
Signature	Date	1 20/2
Signature	 Considered	117690
	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is In conformance with MPEP 609. Draw line through citation if not in conforma copy of this form with next communication to applicant.

Burden Hour Statement: This form is astimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

JAN 0 7 2002

⁵ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.